JP2018153184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018153184A5 JP2018153184A5 JP2018072819A JP2018072819A JP2018153184A5 JP 2018153184 A5 JP2018153184 A5 JP 2018153184A5 JP 2018072819 A JP2018072819 A JP 2018072819A JP 2018072819 A JP2018072819 A JP 2018072819A JP 2018153184 A5 JP2018153184 A5 JP 2018153184A5
- Authority
- JP
- Japan
- Prior art keywords
- network
- data set
- pervasive developmental
- causal
- developmental disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 93
- 208000029560 autism spectrum disease Diseases 0.000 claims description 85
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 77
- 230000014509 gene expression Effects 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000036640 Asperger disease Diseases 0.000 claims description 4
- 201000006062 Asperger syndrome Diseases 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000001364 causal effect Effects 0.000 claims 58
- 230000036755 cellular response Effects 0.000 claims 6
- 230000007613 environmental effect Effects 0.000 claims 5
- 230000005714 functional activity Effects 0.000 claims 5
- 238000012239 gene modification Methods 0.000 claims 4
- 230000005017 genetic modification Effects 0.000 claims 4
- 235000013617 genetically modified food Nutrition 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 208000006289 Rett Syndrome Diseases 0.000 claims 3
- 238000004364 calculation method Methods 0.000 claims 3
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 3
- 238000000126 in silico method Methods 0.000 claims 3
- 238000004088 simulation Methods 0.000 claims 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 2
- 238000013473 artificial intelligence Methods 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 230000010627 oxidative phosphorylation Effects 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- 230000009466 transformation Effects 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000002715 bioenergetic effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000006539 extracellular acidification Effects 0.000 claims 1
- 238000002705 metabolomic analysis Methods 0.000 claims 1
- 230000001431 metabolomic effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000003463 organelle Anatomy 0.000 claims 1
- 230000036284 oxygen consumption Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 description 17
- 239000003550 marker Substances 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000013068 control sample Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606935P | 2012-03-05 | 2012-03-05 | |
| US61/606,935 | 2012-03-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561056A Division JP2015517801A (ja) | 2012-03-05 | 2013-03-05 | 広汎性発達障害の診断および治療のための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020137031A Division JP2020193986A (ja) | 2012-03-05 | 2020-08-14 | 広汎性発達障害の診断および治療のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018153184A JP2018153184A (ja) | 2018-10-04 |
| JP2018153184A5 true JP2018153184A5 (enExample) | 2018-12-20 |
Family
ID=49117277
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561056A Pending JP2015517801A (ja) | 2012-03-05 | 2013-03-05 | 広汎性発達障害の診断および治療のための組成物および方法 |
| JP2018072819A Pending JP2018153184A (ja) | 2012-03-05 | 2018-04-05 | 広汎性発達障害の診断および治療のための組成物および方法 |
| JP2020137031A Pending JP2020193986A (ja) | 2012-03-05 | 2020-08-14 | 広汎性発達障害の診断および治療のための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561056A Pending JP2015517801A (ja) | 2012-03-05 | 2013-03-05 | 広汎性発達障害の診断および治療のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020137031A Pending JP2020193986A (ja) | 2012-03-05 | 2020-08-14 | 広汎性発達障害の診断および治療のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20150023949A1 (enExample) |
| EP (1) | EP2823063A4 (enExample) |
| JP (3) | JP2015517801A (enExample) |
| KR (1) | KR20140140069A (enExample) |
| CN (1) | CN104364393A (enExample) |
| AU (1) | AU2013230045A1 (enExample) |
| CA (1) | CA2866407A1 (enExample) |
| HK (1) | HK1206393A1 (enExample) |
| WO (1) | WO2013134315A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014024537A2 (pt) | 2012-04-02 | 2017-08-08 | Berg Llc | métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese |
| US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US9176113B1 (en) * | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| CA2960837A1 (en) | 2014-09-11 | 2016-03-17 | Berg Llc | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data |
| CN114366759A (zh) * | 2015-05-22 | 2022-04-19 | 亚利桑那大学董事会 | 用于治疗自闭症谱系障碍及相关症状的方法 |
| US11328951B2 (en) | 2016-04-01 | 2022-05-10 | Intel Corporation | Transistor cells including a deep via lined wit h a dielectric material |
| US10650621B1 (en) | 2016-09-13 | 2020-05-12 | Iocurrents, Inc. | Interfacing with a vehicular controller area network |
| CN106885858A (zh) * | 2017-03-10 | 2017-06-23 | 方雷 | 一种高效的痕量临床病人样本的高通量全蛋白组学定量分析方法 |
| CN107312846A (zh) * | 2017-07-12 | 2017-11-03 | 北京赛尔维康生物医学科技有限公司 | Capg和ptgis基因在制备脊柱侧弯检测试剂盒中的应用 |
| CN109212226B (zh) * | 2018-09-06 | 2021-04-06 | 中国人民解放军联勤保障部队第九〇四医院 | 预测急性高山病发病风险的血浆蛋白标志物及其在制备诊断ams易感性试剂盒中的应用 |
| CN109239334A (zh) * | 2018-09-10 | 2019-01-18 | 吉林大学 | 建立时间分辨荧光免疫层析法检测MxA试剂盒 |
| JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ， インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
| WO2020215043A1 (en) * | 2019-04-19 | 2020-10-22 | Yale University | Advanced glycation end-product breaking biocatalysts |
| KR102158009B1 (ko) * | 2019-06-13 | 2020-09-21 | 고려대학교 산학협력단 | 주의력 결핍/과잉행동장애 진단용 마커로서의 14-3-3γ의 용도 |
| CN112442527B (zh) * | 2019-08-27 | 2022-11-11 | 深圳市英马诺生物科技有限公司 | 孤独症诊断试剂盒、基因芯片、基因靶点筛选方法及应用 |
| EP3822974A1 (en) * | 2019-11-15 | 2021-05-19 | Stalicla S.A. | Computational platform to identify therapeutic treatments for neurodevelopmental conditions |
| EP4348265A2 (en) * | 2021-05-25 | 2024-04-10 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Diagnosis of autism spectrum disorder by multiomics platform |
| TWI866002B (zh) * | 2021-12-29 | 2024-12-11 | 財團法人生物技術開發中心 | 反義寡核苷酸及其用途 |
| ES2976116A1 (es) * | 2023-12-15 | 2024-07-23 | Chrmtx Sl | Biomarcadores nucleares de la enfermedad de Alzheimer (EA), sus usos y métodos |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1745149A4 (en) * | 2004-04-15 | 2008-08-06 | Univ Florida | NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS |
| GB0419124D0 (en) * | 2004-08-27 | 2004-09-29 | Proteome Sciences Plc | Methods and compositions relating to Alzheimer's disease |
| AU2006206159A1 (en) * | 2005-01-24 | 2006-07-27 | Massachusetts Institute Of Technology | Method for modeling cell signaling systems by means of bayesian networks |
| EP1840574A1 (en) * | 2006-03-30 | 2007-10-03 | Institut Pasteur | Use of the alpha chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases |
| US20090117562A1 (en) * | 2007-04-09 | 2009-05-07 | Valerie Wailin Hu | Method and kit for diagnosing Autism using gene expression profiling |
| WO2009105718A1 (en) * | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
| US8173369B2 (en) * | 2008-05-15 | 2012-05-08 | The Regents Of The University Of California | Peripheral gene expression biomarkers for autism |
| US20110294693A1 (en) * | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
| US20120178637A1 (en) * | 2009-07-07 | 2012-07-12 | Abbott Laboratories | Biomarkers and methods for detecting alzheimer's disease |
| US20110059861A1 (en) * | 2009-09-08 | 2011-03-10 | Nodality, Inc. | Analysis of cell networks |
| WO2011112961A1 (en) * | 2010-03-12 | 2011-09-15 | Children's Medical Center Corporation | Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns |
| EP2680925B1 (en) * | 2011-03-02 | 2019-11-20 | Berg LLC | Interrogatory cell-based assays and uses thereof |
| WO2013176694A1 (en) * | 2012-05-22 | 2013-11-28 | Berg Pharma Llc | Interrogatory cell-based assays for indentifying drug-induced toxicity markers |
-
2013
- 2013-03-05 HK HK15106693.0A patent/HK1206393A1/xx unknown
- 2013-03-05 CA CA2866407A patent/CA2866407A1/en not_active Abandoned
- 2013-03-05 AU AU2013230045A patent/AU2013230045A1/en not_active Abandoned
- 2013-03-05 EP EP13758001.5A patent/EP2823063A4/en not_active Withdrawn
- 2013-03-05 KR KR20147028035A patent/KR20140140069A/ko not_active Withdrawn
- 2013-03-05 US US14/383,450 patent/US20150023949A1/en not_active Abandoned
- 2013-03-05 CN CN201380022420.3A patent/CN104364393A/zh active Pending
- 2013-03-05 WO PCT/US2013/029201 patent/WO2013134315A1/en not_active Ceased
- 2013-03-05 JP JP2014561056A patent/JP2015517801A/ja active Pending
-
2017
- 2017-12-04 US US15/830,982 patent/US20180275146A1/en not_active Abandoned
-
2018
- 2018-04-05 JP JP2018072819A patent/JP2018153184A/ja active Pending
-
2019
- 2019-02-14 US US16/275,944 patent/US20190242909A1/en not_active Abandoned
-
2020
- 2020-08-14 JP JP2020137031A patent/JP2020193986A/ja active Pending
-
2021
- 2021-06-11 US US17/346,152 patent/US20220137070A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5749171B2 (ja) | バイオマーカー | |
| JP2025172836A (ja) | 自閉症スペクトラム障害のリスクを決定するための方法およびシステム | |
| JP6401702B2 (ja) | 炎症性肝疾患の診断のための方法および組成物 | |
| CN107209184A (zh) | 用于诊断多种感染的标记组合及其使用方法 | |
| JP2011523049A (ja) | 頭頚部癌の同定、モニタリングおよび治療のためのバイオマーカー | |
| JP2015517801A5 (enExample) | ||
| JP2011515666A (ja) | トリプルネガティブ乳がんに関連するｄｎａ修復タンパク質およびその使用法 | |
| CN110273003B (zh) | 一种乳头状肾细胞癌患者预后复发检测标志工具及其风险评估模型的建立 | |
| US10480034B2 (en) | Cancer biomarker and diagnostic | |
| CN117305433A (zh) | 用于快速诊断川崎病的分子生物标志物和分析方法 | |
| IL285031A (en) | Diagnosis of inflammatory bowel diseases | |
| CN116219008A (zh) | 一种肾透明细胞癌的预后评估基因组合及其应用 | |
| KR101346955B1 (ko) | 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트 | |
| CN113444796B (zh) | 与肺癌相关的生物标志物及其在诊断癌症中的应用 | |
| US20160047000A1 (en) | Methods and systems for treatment of ovarian cancer | |
| Zhang et al. | Identification of RNA uridylation subtypes, and the prognostic and therapeutic value of RNA uridylation in systemic lupus erythematosus | |
| Roma et al. | Transcriptome analysis of circulating microRNAs associated with Chagas disease susceptibility and chronic Chagas cardiomyopathy severity | |
| US20160017423A1 (en) | Method and kit for making an in vitro prognosis of severity for a patient in septic shock | |
| HK40119284A (en) | A molecular marker combination for prognosis prediction, prognosis evaluation and/or treatment plan selection of a subject and uses thereof | |
| Casal et al. | Gene signature for the prognosis of colorectal cancer | |
| KR20250166551A (ko) | 대장암 진단용 바이오마커 및 이를 포함한 대장암 진단용 조성물 | |
| HK40090190A (en) | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof | |
| CN119351550A (zh) | 腹膜后脂肪肉瘤预后生物标志物及其应用 | |
| US20140364334A1 (en) | Congestive heart failure biomarkers | |
| CN113430271A (zh) | 预测肾癌患者预后的生物标志物 |